Axon Enterprise, Inc. (NASDAQ:AXON) is Groupama Asset Managment's 10th Largest Position

Groupama Asset Managment boosted its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 0.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 501,260 shares of the biotechnology company's stock after acquiring an additional 1,260 shares during the quarter. Axon Enterprise accounts for about 2.2% of Groupama Asset Managment's portfolio, making the stock its 10th largest position. Groupama Asset Managment owned 0.66% of Axon Enterprise worth $297,909,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AXON. Public Sector Pension Investment Board raised its position in shares of Axon Enterprise by 19.2% during the third quarter. Public Sector Pension Investment Board now owns 3,104 shares of the biotechnology company's stock worth $1,240,000 after acquiring an additional 500 shares during the last quarter. Friedenthal Financial raised its position in shares of Axon Enterprise by 961.7% in the 4th quarter. Friedenthal Financial now owns 1,359 shares of the biotechnology company's stock worth $808,000 after acquiring an additional 1,231 shares in the last quarter. Principal Financial Group Inc. lifted its stake in Axon Enterprise by 33.1% in the third quarter. Principal Financial Group Inc. now owns 136,302 shares of the biotechnology company's stock valued at $54,466,000 after buying an additional 33,869 shares during the period. XTX Topco Ltd lifted its position in shares of Axon Enterprise by 20.6% during the 3rd quarter. XTX Topco Ltd now owns 5,650 shares of the biotechnology company's stock valued at $2,258,000 after acquiring an additional 964 shares during the period. Finally, Artemis Investment Management LLP boosted its position in shares of Axon Enterprise by 21.4% during the 4th quarter. Artemis Investment Management LLP now owns 95,113 shares of the biotechnology company's stock worth $56,528,000 after purchasing an additional 16,792 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock traded down $18.73 during trading hours on Thursday, hitting $539.69. 661,869 shares of the company's stock traded hands, compared to its average volume of 810,044. The stock has a market capitalization of $41.35 billion, a price-to-earnings ratio of 139.46, a PEG ratio of 5.17 and a beta of 1.13. The company has a fifty day simple moving average of $585.99 and a 200-day simple moving average of $552.79. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. Axon Enterprise, Inc. has a 12-month low of $273.52 and a 12-month high of $715.99.

Analysts Set New Price Targets

Several research firms have recently commented on AXON. Needham & Company LLC restated a "buy" rating and set a $600.00 price objective on shares of Axon Enterprise in a report on Wednesday, February 26th. Robert W. Baird boosted their price target on shares of Axon Enterprise from $600.00 to $800.00 and gave the company an "outperform" rating in a research note on Friday, December 6th. Barclays reaffirmed a "hold" rating on shares of Axon Enterprise in a research note on Monday, March 10th. TD Cowen initiated coverage on shares of Axon Enterprise in a research report on Wednesday, January 8th. They set a "buy" rating and a $700.00 target price for the company. Finally, Craig Hallum cut shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $604.67.

Insiders Place Their Bets

In other Axon Enterprise news, Director Jeri Williams sold 307 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $552.72, for a total value of $169,685.04. Following the completion of the sale, the director now directly owns 1,627 shares of the company's stock, valued at $899,275.44. This trade represents a 15.87 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 6.10% of the company's stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.